# Clare L. Scott

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/clare-l-scott/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,366 |
| Field | PARP inhibition in cancer therapy |
| h-index | 70 |
| i10-index | 175 |
| Last Known Institution | The University of Melbourne |
| OpenAlex ID | https://openalex.org/A5085126287 |
| ORCID iD | https://orcid.org/0000-0002-3689-5956 |
| Works | 422 |

## Researcher papers

- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma](https://scholariq.org/papers/i-brca-i-reversion-mutations-in-circulating-tumor-dna-predict-primary-and/)
- [Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)](https://scholariq.org/papers/molecular-and-clinical-determinants-of-response-and-resistance-to-rucaparib-for/)

## Researcher topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)

## Researcher university

- [The University of Melbourne](https://scholariq.org/institutions/the-university-of-melbourne/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.